It was found that serum Nectin-2 levels in patients with both metastatic and non-metastatic CRC have a diagnostic value since there was a significant difference in baseline serum Nectin-2 levels between the whole group patients and the healthy control group (p < 0.001; for all, non-metastatic (stage II or III), and metastatic patients). This evidence concerns the gene NECTIN2 and colorectal carcinoma.